# Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

> **NCT02824718** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 16 (actual)

## Conditions studied

- Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment

## Interventions

- **DRUG:** Teriparatide
- **DRUG:** Thiazide
- **DRUG:** Potassium sparing diuretic
- **DRUG:** Alfacalcidol

## Key facts

- **NCT ID:** NCT02824718
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-06
- **Primary completion:** 2020-05-28
- **Final completion:** 2020-05-28
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824718, "Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02824718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*